5 Key Takeaways

• 1

  CD19 CAR T therapy reduced disease activity in six patients with severe, treatment-refractory rheumatoid arthritis in a phase I trial.

• 2

  Three participants maintained remission without medication during follow-up, which lasted between 36 and 52 weeks.

• 3

  The study reported a median disease activity score reduction of 49% at week 24 and 34% at the latest follow-up.

• 4

  All participants experienced grade 1 or 2 cytokine release syndrome, which resolved, with no severe adverse events reported.

• 5

  The study will advance to a phase II trial comparing CD19 CAR T therapy with rituximab in ten additional patients.